MEGAN BURKLE: Open Payments
NPI 1457198665 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,619 in 92 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $125 · 2025 $1,619
Food & beverage: $1,520Education: $99
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 26 | $432 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $193 |
| ABBVIE INC. | 7 | $175 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $112 |
| Regeneron Healthcare Solutions, Inc. | 4 | $100 |
| Gilead Sciences, Inc. | 4 | $98 |
| GENZYME CORPORATION | 4 | $93 |
| Ipsen Biopharmaceuticals, Inc | 3 | $74 |
| Celltrion USA Inc. | 4 | $61 |
| Lilly USA, LLC | 3 | $55 |
Products named: TREMFYA, DUPIXENT, ENTYVIO, SKYRIZI, XIFAXAN, IQIRVO, VEGZELMA, OMVOH.
Industry payments across NE — which companies pay providers there.
